Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-α inhibitor
Keun Bum Chung, Eun Young Lee, Jong Pil Im, Sung Koo Han, Jae-Joon Yim
Korean J Intern Med. 2013;28(2):174-179. Published online 2013 Feb 27 DOI: https://doi.org/10.3904/kjim.2013.28.2.174
Citations to this article as recorded by 
Canadian Consensus Recommendations for the Management of Operable Stage II/III Non-Small-Cell Lung Cancer: Results of a Modified Delphi Process
James Tankel, Jonathan Spicer, Quincy Chu, Pierre Olivier Fiset, Biniam Kidane, Natasha B. Leighl, Philippe Joubert, Donna Maziak, David Palma, Anna McGuire, Barbara Melosky, Stephanie Snow, Houda Bahig, Normand Blais
Current Oncology.2023; 30(12): 10363. CrossRef
Novel treatments for inflammatory bowel disease
Hyo Sun Lee, Soo-Kyung Park, Dong Il Park
The Korean Journal of Internal Medicine.2018; 33(1): 20. CrossRef
Incidence of Active Tuberculosis within One Year after Tumor Necrosis Factor Inhibitor Treatment according to Latent Tuberculosis Infection Status in Patients with Inflammatory Bowel Disease
Jieun Kang, Dae Hyun Jeong, Minkyu Han, Suk-Kyun Yang, Jeong-Sik Byeon, Byong Duk Ye, Sang Hyoung Park, Sung Wook Hwang, Tae Sun Shim, Kyung-Wook Jo
Journal of Korean Medical Science.2018;[Epub] CrossRef
Efficacy of Treatment for Latent Tuberculosis in Patients Undergoing Treatment with a Tumor Necrosis Factor Antagonist
Jungsil Lee, Eunyoung Kim, Eun Jin Jang, Chang-Hoon Lee, Eun Young Lee, Jong Pil Im, Sung Koo Han, Jae-Joon Yim
Annals of the American Thoracic Society.2017; 14(5): 690. CrossRef
Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease
Jang Wook Lee, Chang Hwan Choi, Ji Hoon Park, Jeong Wook Kim, Sang Bum Kang, Ja Seol Koo, Young-Ho Kim, You Sun Kim, Young Eun Joo, Sae Kyung Chang
Intestinal Research.2016; 14(2): 146. CrossRef
Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor
Ja Min Byun, Chang Kyun Lee, Sang Youl Rhee, Hyo-Jong Kim, Jong Pil Im, Dong Il Park, Chang Soo Eun, Sung-Ae Jung, Jeong Eun Shin, Kang-Moon Lee, Jae Hee Cheon
Scandinavian Journal of Gastroenterology.2015; 50(3): 312. CrossRef
Inflammatory Bowel Disease Cohort Studies in Korea: Present and Future
Jung Won Lee, Jong Pil Im, Jae Hee Cheon, You Sun Kim, Joo Sung Kim, Dong Soo Han
Intestinal Research.2015; 13(3): 213. CrossRef
The Risk of Tuberculosis in Korean Patients with Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-α Blockers
Ja Min Byun, Chang Kyun Lee, Sang Youl Rhee, Hyo-Jong Kim, Jung-Wook Kim, Jae-Jun Shim, Jae Young Jang
Journal of Korean Medical Science.2015; 30(2): 173. CrossRef
Evaluation of the usefulness of interferon‐gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents
Jae‐Hoon Kim, Soyoung Won, Chan‐Bum Choi, Yoon‐Kyoung Sung, Gwan Gyu Song, Sang‐Cheol Bae
International Journal of Rheumatic Diseases.2015; 18(3): 315. CrossRef
Mycobacterial diseases developed during anti-tumour necrosis factor-α therapy
Jung-Wan Yoo, Kyung-Wook Jo, Bo-Hyung Kang, Mi Young Kim, Bin Yoo, Chang-Keun Lee, Yong-Gil Kim, Suk-Kyun Yang, Jeong-Sik Byeon, Kyung-Jo Kim, Byong Duk Ye, Tae Sun Shim
European Respiratory Journal.2014; 44(5): 1289. CrossRef
Patients treated with a tumor necrosis factor-α inhibitor are more likely to develop extrapulmonary tuberculosis
Sang-Oh Lee
The Korean Journal of Internal Medicine.2013; 28(2): 159. CrossRef